D-Wave Quantum: A Securities Suit, a 19% Bookings Slide and the Case for Patience

D-Wave Quantum shareholders now have two separate files to keep open: a commercial one and a legal one. The company's mixed third-quarter 2026 results, released Tuesday, weighed on the stock, which closed Wednesday down 2.8%. On top of that, the law firm Pomerantz disclosed a securities class action against the company and certain executives, filed in the federal court for the Northern District of California. The allegations remain just that — allegations, not established facts.

The quarter in three numbers

The headline figures pull in different directions. Revenue for the third quarter of 2026 climbed 21% to $4.51 million, ahead of expectations. Bookings, however, fell 19% year over year to $1.9 million — the metric that tracks freshly signed business and the one that matters most for anyone betting on future momentum. The bottom line offered little comfort: a loss of $0.13 per share, against a consensus forecast of $0.10, meaning the company missed earnings estimates despite the stronger top line.

Those three data points frame the central debate. Revenue growth suggests commercial traction; the bookings decline suggests the pipeline of new contracts is thinning; the wider loss suggests that additional revenue has yet to translate into better economics.

A backlog that buys time

Where the bull case finds its footing is in the remaining performance obligations. D-Wave put these at $38.3 million for the third quarter of 2026, an increase of 1,221% over the prior year. That is a substantial store of contracted work not yet recognized as revenue — a bridge between business already booked and sales still to come.

The nine-month picture reinforces the point. Bookings over that stretch reached $37.4 million, up 611% year over year. On its own, that figure argues that D-Wave has expanded its business considerably over the past year. The question is whether the next few quarters sustain that trajectory or mark a peak.

For the optimistic reading to hold, two things need to happen together: the backlog must convert into revenue, and new bookings must start growing again. A large backlog creates visibility; fresh contracts extend it. Only the combination keeps the growth thesis intact.

Stride, and what a faster solver is worth

A possible catalyst arrived on November 4, when the company announced an improved version of its hybrid Stride solver. According to D-Wave, the new release found better solutions to production-line takt scheduling problems in 15 seconds than the previous version managed in 120 seconds.

The commercial value depends on whether customers judge that performance gain worth paying for. In a favorable scenario, the upgraded offering makes new deals easier to close — and a recovering bookings line would then link technical progress to business success. That link is precisely what the cautious camp wants to see before granting the stock the benefit of the doubt.

The Street is positive, but less so

Analyst actions this week captured the mood. Wedbush confirmed its Outperform rating and $30 price target on Wednesday, a vote of confidence in the wake of the quarterly report. B. Riley Securities took a different tack on Monday, cutting its price target from $27 to $22 while keeping its Buy rating.

A lower target paired with an unchanged recommendation reads as a more guarded form of optimism. Both stances would gain credibility if D-Wave pairs revenue growth with progress on new business. Until then, the improved products need to show up in signed contracts.

What could go wrong

The bear case rests on the direction of bookings. If the decline continues, the investment case increasingly depends on working through the existing backlog — a store of value whose continuation would first have to be re-underwritten by new business. Persistent losses would sharpen that concern. A combination of weak bookings and ongoing losses could leave even rising revenue unable to dispel doubts about the road ahead.

The class action adds a second layer to the risk calculus. Its outcome is unresolved, and the claims have not been tested in court. Investors should treat the litigation as an additional uncertainty that a positive thesis must be strong enough to absorb.

The dates that matter

Pomerantz has set December 15, 2026 as the deadline for motions to be appointed lead plaintiff — a procedural step that should be weighted accordingly, not read as a verdict on the merits. On the operating side, the next meaningful catalysts are further disclosures on bookings, revenue and earnings. A rebound in orders would validate the strong nine-month comparison; another decline would intensify the question of how durable growth beyond the backlog really is.

For now, the stock represents a conditional opportunity. It gains substance if commercial progress follows the technical kind — and if the courtroom file stays separate from the business one.